{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:16:14Z","timestamp":1788434174284,"version":"build-2803163510"},"reference-count":64,"publisher":"American Chemical Society (ACS)","issue":"17","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI147325"],"award-info":[{"award-number":["AI147325"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI157046"],"award-info":[{"award-number":["AI157046"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158775"],"award-info":[{"award-number":["AI158775"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Conspectus<\/jats:title>\n                  <jats:p>SARS-CoV-2 papain-like protease (PLpro) is a compelling but historically underdeveloped antiviral target. Unlike the viral main protease (Mpro), which rapidly became the focus of intensive drug-discovery efforts and yielded clinical candidates and approved drugs, PLpro posed a more challenging medicinal chemistry problem: a shallow, flexible substrate-recognition surface and a mobile BL2 loop. Nevertheless, PLpro is a high-profile drug target because it is vital for viral replication by processing viral polyproteins and suppresses host innate immunity through deubiquitinating and deISGylating activities. These dual functions make PLpro more than a viral protease; it is a multifunctional immune-evasion enzyme whose inhibition could both block virus replication and restore antiviral host responses.<\/jats:p>\n                  <jats:p>This Account summarizes our group\u2019s effort to convert PLpro from a challenging target into a tractable antiviral drug-discovery platform. We began by developing and applying orthogonal assays to identify specific PLpro inhibitors and triage false positives. High-throughput screening and drug-repurposing campaigns yielded early hits, including Jun9722, Jun9754, and tropifexor, but also revealed that biochemical inhibition alone was insufficient to predict cellular antiviral activity. This motivated us to develop a FlipGFP cell-based reporter assay as a BSL-2-compatible bridge between enzymology and live-virus studies. In addition, we later developed a fluorescence polarization assay using a fluorescein-labeled PLpro ligand to enable direct, high-throughput quantification of inhibitor binding. Together with FRET enzymatic assays, thermal shift experiments, cellular FlipGFP assays, and antiviral assays, these tools established a rigorous validation framework for PLpro medicinal chemistry.<\/jats:p>\n                  <jats:p>With this platform in place, we pursued structure-based PLpro inhibitor design. Early cocrystal structures showed that potent noncovalent inhibitors engage the BL2 groove and stabilize inhibitor-bound PLpro conformations. A major conceptual advance came from structural analysis of the Jun11313-bound PLpro complex, which revealed that an inhibitor substituent occupied a hydrophobic surface pocket corresponding to the Val70 position of ubiquitin. We designated this newly recognized region the Val70Ub pocket. Exploiting this pocket transformed PLpro inhibitor design by expanding ligand engagement beyond the canonical BL2 groove and enabling substantial gains in enzymatic inhibition and antiviral activity.<\/jats:p>\n                  <jats:p>This design principle led to orally active noncovalent inhibitors, including Jun12682 and the quinoline lead Jun13296, both of which showed potent enzymatic inhibition, cellular antiviral activity, favorable mouse pharmacokinetics, and protection in SARS-CoV-2 mouse infection models. We further extended the Val70Ub-centered recognition strategy to covalent inhibitor design by appending cysteine-reactive warheads (covalent electrophiles) to optimized noncovalent scaffolds, thereby generating compounds that retained BL2 groove and Val70Ub binding while engaging the catalytic Cys111. Finally, resistance studies identified E167, Y268, and Q269 as drug resistance hotspots, highlighting the need to design inhibitors that engage less mutation-sensitive binding sites.<\/jats:p>\n                  <jats:p>Overall, this Account illustrates how integrated assay development, structural biology, medicinal chemistry, pharmacology, virology, and resistance analysis can transform a challenging viral deubiquitinase into a credible antiviral target. The lessons from PLpro should inform future efforts to design broad-spectrum coronavirus PLpro inhibitors and to target other viral protease\u2013deubiquitinase enzymes with shallow, flexible binding surfaces.<\/jats:p>","DOI":"10.1021\/acs.accounts.6c00361","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T21:02:07Z","timestamp":1787086927000},"page":"2773-2784","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2\nPapain-Like Protease: Drug Design,\nAssay Development, and Drug Resistance"],"prefix":"10.1021","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-4621","authenticated-orcid":true,"given":"Jun","family":"Wang","sequence":"first","affiliation":[{"name":"Rutgers, the State University of New Jersey , , , ,","place":["Piscataway, New Jersey, United States, 08854"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Li","sequence":"additional","affiliation":[{"name":"Rutgers, the State University of New Jersey , , , ,","place":["Piscataway, New Jersey, United States, 08854"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-6962","authenticated-orcid":true,"given":"Bin","family":"Tan","sequence":"additional","affiliation":[{"name":"Rutgers, the State University of New Jersey , , , ,","place":["Piscataway, New Jersey, United States, 08854"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"1","key":"2026090306315382900_cit1","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1038\/s41467-025-59922-9","article-title":"Identification\nof naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like\nprotease","volume":"16","author":"Tan","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"2026090306315382900_cit2","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41467-025-56902-x","article-title":"Design of quinoline\nSARS-CoV-2 papain-like protease inhibitors as\noral antiviral drug candidates","volume":"16","author":"Jadhav","year":"2025","journal-title":"Nat. Commun."},{"issue":"22","key":"2026090306315382900_cit3","doi-asserted-by":"publisher","first-page":"20399","DOI":"10.1021\/acs.jmedchem.4c01872","article-title":"Structure-Based\nDesign of Covalent SARS-CoV-2 Papain-like Protease Inhibitors","volume":"67","author":"Tan","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6690","key":"2026090306315382900_cit4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1126\/science.adm9724","article-title":"Design\nof a SARS-CoV-2 papain-like protease inhibitor with antiviral\nefficacy in a mouse model","volume":"383","author":"Tan","year":"2024","journal-title":"Science"},{"issue":"7","key":"2026090306315382900_cit5","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","article-title":"Discovery\nof SARS-CoV-2 Papain-like Protease\nInhibitors through a Combination of High-Throughput Screening and\na FlipGFP-Based Reporter Assay","volume":"7","author":"Ma","year":"2021","journal-title":"ACS Cent Sci."},{"key":"2026090306315382900_cit6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic\nstrategies for COVID-19: Progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026090306315382900_cit7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history,\nmechanism, and perspectives of nirmatrelvir\n(PF-07321332): an orally bioavailable main protease inhibitor used\nin combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res."},{"issue":"1","key":"2026090306315382900_cit8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1039\/D3MD00493G","article-title":"On the\norigins of SARS-CoV-2 main protease inhibitors","volume":"15","author":"Janin","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"1","key":"2026090306315382900_cit9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1021\/jacsau.5c01178","article-title":"Structure-Based Design of Covalent SARS-CoV-2 Main Protease Inhibitors\nTargeting the Nirmatrelvir-Resistant E166 Mutants","volume":"6","author":"Cai","year":"2026","journal-title":"JACS Au"},{"issue":"2","key":"2026090306315382900_cit10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1021\/acs.accounts.2c00735","article-title":"SARS-CoV-2\nMain Protease Drug Design, Assay Development, and Drug Resistance\nStudies","volume":"56","author":"Tan","year":"2023","journal-title":"Acc. Chem. Res."},{"key":"2026090306315382900_cit11","doi-asserted-by":"publisher","first-page":"115667","DOI":"10.1016\/j.ejmech.2023.115667","article-title":"Exploring\ndiverse reactive\nwarheads for the design of SARS-CoV-2 main protease inhibitors","volume":"259","author":"Tan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"49","key":"2026090306315382900_cit12","doi-asserted-by":"publisher","first-page":"20697","DOI":"10.1021\/jacs.1c08060","article-title":"Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main\nProtease Inhibitors with High Target Specificity","volume":"143","author":"Ma","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"2026090306315382900_cit13","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1021\/acsptsci.1c00099","article-title":"Rational Design of Hybrid SARS-CoV-2\nMain Protease Inhibitors Guided\nby the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors\nGC-376, Telaprevir, and Boceprevir","volume":"4","author":"Xia","year":"2021","journal-title":"ACS Pharmacol\nTransl Sci."},{"issue":"50","key":"2026090306315382900_cit14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy\nfor developing dual inhibitors against M(pro) and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"issue":"8","key":"2026090306315382900_cit15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir,\nGC-376, and calpain inhibitors II, XII\ninhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"2026090306315382900_cit16","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00162-20","article-title":"Remdesivir\nagainst COVID-19 and Other Viral Diseases","volume":"34","author":"Malin","year":"2020","journal-title":"Clin Microbiol Rev."},{"issue":"6575","key":"2026090306315382900_cit17","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An\noral SARS-CoV-2 M(pro)\ninhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"10","key":"2026090306315382900_cit18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history,\nmechanism, and perspectives\nof nirmatrelvir (PF-07321332): an orally bioavailable main protease\ninhibitor used in combination with ritonavir to reduce COVID-19-related\nhospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res."},{"issue":"11","key":"2026090306315382900_cit19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug Development\nand Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19\nTherapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem."},{"key":"2026090306315382900_cit20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like\nprotease: Structure, function and inhibition by designed antiviral\ncompounds","volume":"115","author":"Ba\u0301ez-Santos","year":"2015","journal-title":"Antiviral Res."},{"issue":"11","key":"2026090306315382900_cit21","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and Challenges\nin Targeting the SARS-CoV-2 Papain-like Protease","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"16","key":"2026090306315382900_cit22","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300216","article-title":"A Patent Review on SARS Coronavirus\nPapain-Like Protease (PL(pro)) Inhibitors","volume":"18","author":"Brian Chia","year":"2023","journal-title":"ChemMedChem."},{"issue":"1","key":"2026090306315382900_cit23","doi-asserted-by":"publisher","first-page":"103832","DOI":"10.1016\/j.drudis.2023.103832","article-title":"Targeting SARS-CoV-2 nonstructural protein 3: Function, structure,\ninhibition, and perspective in drug discovery","volume":"29","author":"Li","year":"2024","journal-title":"Drug Discov Today"},{"key":"2026090306315382900_cit24","doi-asserted-by":"publisher","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class\nof papain-like protease\/deubiquitinase\ninhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"Proc.\nNatl. Acad. Sci. U.S.A."},{"key":"2026090306315382900_cit25","doi-asserted-by":"publisher","first-page":"116011","DOI":"10.1016\/j.ejmech.2023.116011","article-title":"Structure-based design of SARS-CoV-2 papain-like\nprotease inhibitors","volume":"264","author":"Jadhav","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"42","key":"2026090306315382900_cit26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity\nprofiling and crystal structures of inhibitor-bound SARS-CoV-2\npapain-like protease: A framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci. Adv."},{"issue":"18","key":"2026090306315382900_cit27","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease,\nPLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"key":"2026090306315382900_cit28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread\nand innate immunity","volume":"587","author":"Shin","year":"2022","journal-title":"Nature"},{"issue":"1","key":"2026090306315382900_cit29","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1038\/s41467-023-38031-5","article-title":"Dual domain\nrecognition\ndetermines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked\ndi-ubiquitin","volume":"14","author":"Wydorski","year":"2023","journal-title":"Nat. Commun."},{"key":"2026090306315382900_cit30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2\nPLpro reveals a hot\nspot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"2026090306315382900_cit31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure\nof papain-like protease from SARS-CoV-2\nand its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"2026090306315382900_cit32","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1021\/acsinfecdis.1c00629","article-title":"Drug-Repurposing Screening\nIdentified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor","volume":"8","author":"Ma","year":"2022","journal-title":"ACS Infect Dis"},{"issue":"2","key":"2026090306315382900_cit33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1021\/acsptsci.1c00240","article-title":"Validation and Invalidation\nof SARS-CoV-2 Papain-like Protease Inhibitors","volume":"5","author":"Ma","year":"2022","journal-title":"ACS Pharmacol Transl Sci."},{"issue":"11","key":"2026090306315382900_cit34","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13238-021-00836-9","article-title":"High-throughput\nscreening identifies established drugs as SARS-CoV-2 PLpro inhibitors","volume":"12","author":"Zhao","year":"2021","journal-title":"Protein Cell"},{"issue":"1","key":"2026090306315382900_cit35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.7b00903","article-title":"Seven Year Itch:\nPan-Assay Interference Compounds (PAINS)\nin 2017-Utility and Limitations","volume":"13","author":"Baell","year":"2018","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"2026090306315382900_cit36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/adt.2015.674","article-title":"How to Triage PAINS-Full Research","volume":"14","author":"Dahlin","year":"2016","journal-title":"Assay Drug Dev Technol."},{"issue":"5","key":"2026090306315382900_cit37","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1021\/jm5019093","article-title":"PAINS in the assay:\nchemical mechanisms of assay interference and promiscuous enzymatic\ninhibition observed during a sulfhydryl-scavenging HTS","volume":"58","author":"Dahlin","year":"2015","journal-title":"J. Med. Chem."},{"issue":"12","key":"2026090306315382900_cit38","doi-asserted-by":"publisher","first-page":"10263","DOI":"10.1021\/acs.jmedchem.4c00597","article-title":"Colloidal\nAggregation Confounds Cell-Based Covid-19 Antiviral Screens","volume":"67","author":"Glenn","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026090306315382900_cit39","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro Inhibitors for COVID-19\nAntiviral Therapy Leveraging Binding Cooperativity","volume":"65","author":"Shen","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026090306315382900_cit40","doi-asserted-by":"publisher","first-page":"102323","DOI":"10.1016\/j.xpro.2023.102323","article-title":"FlipGFP protease\nassay for evaluating in vitro inhibitory\nactivity against SARS-CoV-2 M(pro) and PL(pro)","volume":"4","author":"Tan","year":"2023","journal-title":"STAR Protoc"},{"issue":"3","key":"2026090306315382900_cit41","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1021\/acsptsci.4c00642","article-title":"Development\nof a Fluorescence Polarization Assay for the SARS-CoV-2 Papain-like\nProtease","volume":"8","author":"Li","year":"2025","journal-title":"ACS Pharmacol Transl Sci."},{"issue":"3","key":"2026090306315382900_cit42","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1021\/acs.jmedchem.5c03704","article-title":"Discovery of Spiro[chromane-2,4\u2019-piperidine]\nDerivatives as Irreversible Inhibitors of SARS-CoV-2 Papain-like Protease","volume":"69","author":"Wei","year":"2026","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026090306315382900_cit43","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1021\/acs.jmedchem.5c01973","article-title":"Structure-Guided Design of Potent and\nSelective Covalent Inhibitors Targeting the SARS-CoV-2 Papain-like\nProtease","volume":"69","author":"Sharafi","year":"2026","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026090306315382900_cit44","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1021\/acs.jmedchem.5c02832","article-title":"Discovery\nof Fragment-Based Inhibitors of SARS-CoV-2\nPL(Pro)","volume":"69","author":"Wei","year":"2026","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026090306315382900_cit45","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1021\/acsmedchemlett.5c00482","article-title":"Targeting\nthe S1\u2019 Pocket of SARS-CoV-2 Papain-Like Protease Yields Highly\nPotent Inhibitors","volume":"16","author":"Garad","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"issue":"49","key":"2026090306315382900_cit46","doi-asserted-by":"publisher","first-page":"33983","DOI":"10.1021\/jacs.4c12992","article-title":"Covalent DNA-Encoded Library Workflow Drives Discovery of SARS-CoV-2\nNonstructural Protein Inhibitors","volume":"146","author":"Wang","year":"2024","journal-title":"J. Am. Chem.\nSoc."},{"key":"2026090306315382900_cit47","doi-asserted-by":"publisher","first-page":"116963","DOI":"10.1016\/j.ejmech.2024.116963","article-title":"Naphthalen-1-ylethanamine-containing\nsmall molecule inhibitors of the papain-like protease of SARS-CoV-2","volume":"280","author":"Shinohara","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"2026090306315382900_cit48","doi-asserted-by":"publisher","first-page":"13681","DOI":"10.1021\/acs.jmedchem.4c00378","article-title":"Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like\nProtease (PLpro): In Vitro and In Vivo Antiviral Activity","volume":"67","author":"Velma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026090306315382900_cit49","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1016\/j.apsb.2024.04.011","article-title":"Discovery and characterization of novel potent\nnon-covalent small\nmolecule inhibitors targeting papain-like protease from SARS-CoV-2","volume":"14","author":"Zheng","year":"2024","journal-title":"Acta Pharm. Sin B"},{"issue":"4","key":"2026090306315382900_cit50","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1021\/acsmedchemlett.4c00069","article-title":"Chemical Space Profiling\nof SARS-CoV-2 PL(pro) Using DNA-Encoded\nFocused Libraries","volume":"15","author":"Wang","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"2026090306315382900_cit51","doi-asserted-by":"publisher","first-page":"8433","DOI":"10.1021\/acs.jmedchem.5c03846","article-title":"Discovery of the SARS-CoV-2 Papain-Like Protease Inhibitor\nMR1\u2013114: From Structure-Based Design to In Vivo Antiviral Efficacy","volume":"69","author":"Gannarapu","year":"2026","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026090306315382900_cit52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68795-5","article-title":"YL1004 is a SARS-CoV-2\npapain-like protease inhibitor with immunomodulatory and antiviral\nactivity in mice","volume":"17","author":"Nan","year":"2026","journal-title":"Nat. Commun."},{"issue":"1","key":"2026090306315382900_cit53","doi-asserted-by":"publisher","first-page":"10169","DOI":"10.1038\/s41467-024-54462-0","article-title":"Discovery of orally bioavailable SARS-CoV-2 papain-like\nprotease inhibitor as a potential treatment for COVID-19","volume":"15","author":"Lu","year":"2024","journal-title":"Nat. Commun."},{"issue":"35","key":"2026090306315382900_cit54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado4288","article-title":"Discovery of SARS-CoV-2\npapain-like protease (PL(pro)) inhibitors with efficacy in a murine\ninfection model","volume":"10","author":"Garnsey","year":"2024","journal-title":"Sci. Adv."},{"issue":"1","key":"2026090306315382900_cit55","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1038\/s41467-024-50566-9","article-title":"Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements\nfor function, structure, and drug escape","volume":"15","author":"Wu","year":"2024","journal-title":"Nat.\nCommun."},{"issue":"6","key":"2026090306315382900_cit56","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals\nand Beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem. Rev."},{"key":"2026090306315382900_cit57","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.antiviral.2018.07.020","article-title":"Comparison\nof antiviral resistance across acute and chronic viral infections","volume":"158","author":"Mason","year":"2018","journal-title":"Antiviral Res."},{"issue":"8","key":"2026090306315382900_cit58","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1021\/acsmedchemlett.4c00238","article-title":"Fragment-Based Screen of SARS-CoV-2 Papain-like Protease (PL(pro))","volume":"15","author":"Taylor","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"11","key":"2026090306315382900_cit59","doi-asserted-by":"publisher","first-page":"107821","DOI":"10.1016\/j.jbc.2024.107821","article-title":"Identification of novel allosteric\nsites of SARS-CoV-2 papain-like protease (PLpro) for the development\nof COVID-19 antivirals","volume":"300","author":"Ferreira","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"1","key":"2026090306315382900_cit60","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s42003-022-03737-7","article-title":"Antiviral\nactivity of natural phenolic compounds in\ncomplex at an allosteric site of SARS-CoV-2 papain-like protease","volume":"5","author":"Srinivasan","year":"2022","journal-title":"Commun. Biol."},{"issue":"52","key":"2026090306315382900_cit61","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202212378","article-title":"Identification of Cysteine\n270 as a Novel Site for Allosteric Modulators of SARS-CoV-2 Papain-Like\nProtease","volume":"61","author":"Hu","year":"2022","journal-title":"Angew. Chem., Int. Ed. Engl."},{"issue":"1","key":"2026090306315382900_cit62","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1038\/s41467-025-57905-4","article-title":"A novel PLpro inhibitor improves outcomes in a pre-clinical\nmodel of long COVID","volume":"16","author":"S","year":"2025","journal-title":"Nat. Commun."},{"key":"2026090306315382900_cit63","doi-asserted-by":"publisher","first-page":"199368","DOI":"10.1016\/j.virusres.2024.199368","article-title":"Viral deubiquitinating\nproteases and the promising strategies of their inhibition","volume":"344","author":"van Vliet","year":"2024","journal-title":"Virus Res."},{"issue":"22","key":"2026090306315382900_cit64","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1016\/j.jmb.2017.06.010","article-title":"Structure and Function\nof Viral Deubiquitinating Enzymes","volume":"429","author":"Bailey-Elkin","year":"2017","journal-title":"J. Mol. Biol."}],"container-title":["Accounts of Chemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.accounts.6c00361","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/achre4\/article-pdf\/59\/17\/2773\/66855270\/acs.accounts.6c00361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/achre4\/article-pdf\/59\/17\/2773\/66855270\/acs.accounts.6c00361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:32:06Z","timestamp":1788431526000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/achre4\/article\/59\/17\/2773\/5275786\/SARS-CoV-2-Papain-Like-Protease-Drug-Design-Assay"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":64,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.accounts.6c00361","relation":{},"ISSN":["0001-4842","1520-4898"],"issn-type":[{"value":"0001-4842","type":"print"},{"value":"1520-4898","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}